China’s NMPA announces full-chain drug safety regulation upgrade for 15th Five-Year Plan
On September 20, China’s National Medical Products Administration (NMPA) announced plans to upgrade full-chain drug safety regulation during the 15th Five-Year Plan period. The agency will revise laws including the Medical Device Management Law, compile the 2030 Chinese Pharmacopoeia prioritizing essential and high-risk drugs, and develop standards for cutting-edge fields like brain-computer interfaces.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary covers the current reports
Cross-source coverage
Reporting timeline
China NMPA Plans Full-Chain Drug Safety Regulation Upgrade During 15th Five-Year Plan
On September 20, Yang Sheng, Deputy Commissioner of China's National Medical Products Administration (NMPA), announced at a State Council Information Office press conference that during the 15th Five-Year Plan period, the agency will issue and refine opinions on improving the drug safety responsibility system. The NMPA plans to advance revisions to laws and regulations including the Medical Device Management Law and the Regulations on Protection of Traditional Chinese Medicine Varieties, fully implement the Implementation Regulations of the Drug Administration Law, and improve supporting systems. A key initiative is an action plan to upgrade standards for drugs and medical devices, including compiling the 2030 edition of the Chinese Pharmacopoeia, which will prioritize inclusion of essential medicines, insurance-covered drugs, and high-risk formulations. The agency will also strengthen research and development of standards in cutting-edge fields such as brain-computer interfaces, aiming to drive quality improvements through upgraded standards across the entire drug safety chain.
Read sourceChina's NMPA Plans Full-Chain Drug Safety Regulation Upgrade During 15th Five-Year Plan
On September 20, Yang Sheng, Deputy Commissioner of China's National Medical Products Administration (NMPA), announced at a State Council Information Office press conference that during the '15th Five-Year Plan' period, the NMPA will issue opinions to improve the drug safety responsibility system. The agency will advance revisions to laws and regulations including the Medical Device Management Law and the Regulations on Protection of Traditional Chinese Medicine Varieties, fully implement the Implementation Regulations of the Drug Administration Law, and refine supporting systems. A key initiative is an action plan for upgrading standards for drugs and medical devices, which includes compiling the 2030 edition of the Chinese Pharmacopoeia, prioritizing essential medicines, medicines covered by medical insurance, and high-risk preparation varieties. The NMPA will also strengthen efforts in researching and formulating standards for cutting-edge fields such as brain-computer interfaces, using upgraded standards to drive quality improvements.
Read sourceChina NMPA Plans Drug Safety Reforms, Standard Upgrades During 15th Five-Year Plan
On September 20, Yang Sheng, Deputy Director of China's National Medical Products Administration (NMPA), announced at a State Council Information Office press conference that during the 15th Five-Year Plan period, the agency will issue opinions to improve the drug safety responsibility system. The NMPA plans to advance revisions to laws including the Medical Device Management Law and the Regulations on Protection of Traditional Chinese Medicine Varieties, fully implement the Drug Administration Law's Implementation Regulations, and refine supporting systems. A new action plan will upgrade standards for drugs and medical devices, and the 2030 edition of the Chinese Pharmacopoeia will be compiled with priority inclusion of essential medicines, medical insurance-covered drugs, and high-risk formulations. The NMPA will also strengthen research and development of standards in cutting-edge fields such as brain-computer interfaces, aiming to drive quality improvements through upgraded standards.
Show 2 older updatesHide older updates
China's NMPA Plans Drug Safety Overhaul, New Pharmacopoeia, and Brain-Computer Interface Standards
On September 20, Yang Sheng, Deputy Commissioner of the National Medical Products Administration (NMPA), announced at a State Council Information Office press conference that during China's 15th Five-Year Plan period, the agency will issue opinions to improve the drug safety responsibility system. Revisions to laws including the Medical Device Management Law and the Regulations on Protection of Traditional Chinese Medicine Varieties will be advanced. The NMPA will fully implement the Implementation Regulations of the Drug Administration Law and launch an action plan to upgrade drug and medical device standards. The 2030 edition of the Chinese Pharmacopoeia will be compiled, prioritizing essential medicines, drugs covered by medical insurance, and high-risk formulations. Additionally, the NMPA will strengthen research and formulation of standards for cutting-edge fields such as brain-computer interfaces, using upgraded standards to drive quality improvements.
Read sourceChina's NMPA to Upgrade Full-Chain Drug Safety Regulation During 15th Five-Year Plan
At a State Council Information Office press conference on September 20, Yang Sheng, Deputy Director of China's National Medical Products Administration (NMPA), announced plans to upgrade full-chain, whole-process drug safety regulation during the 15th Five-Year Plan period. The NMPA will issue opinions to improve the drug safety responsibility system, advance revisions to laws including the Medical Device Management Law and the Regulations on Protection of Traditional Chinese Medicine Varieties, and fully implement the Implementation Regulations of the Drug Administration Law. An action plan for upgrading standards for drugs and medical devices will be carried out, and the 2030 edition of the Chinese Pharmacopoeia will be compiled, prioritizing essential medicines, medical insurance-listed drugs, and high-risk preparation varieties. The NMPA will also strengthen research and formulation of standards in cutting-edge fields such as brain-computer interfaces, using upgraded standards to drive quality improvements.
Read source